Canada Pension Plan Investment Board, a global investment management organization, agreed to invest $100m in Hutchison China MediTech, an innovative, commercial-stage, biopharmaceutical company. “This placement aligns with CPP Investments’ focus on providing strategic, long-term capital to industry leading companies where we can participate in the future success of the business and help create greater value through ongoing partnership. We look forward to supporting Chi-Med’s work on innovation in oncology treatment," Agus Tandiono, CPP Investments Managing Director and Head of Fundamental Equities Asia.